EN DE
STOCK COMPARISON

Xeris Pharmaceuticals vs Jiangsu Hengrui Medicine Co: Fair Value & Quality

Both stocks run through our valuation models. Here is how Xeris Pharmaceuticals (XERS) and Jiangsu Hengrui Medicine Co (600276) compare, as of Aug 8, 2026.

As of Aug 8, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Xeris Pharmaceuticals trades at $7.36 versus a fair value of $1.96 (-73%), while Jiangsu Hengrui Medicine Co trades at ¥52.11 versus ¥25.94 (-50%).
Xeris Pharmaceuticals
XERS · USD · Health Care
-73%
upside to fair value
overvalued
Price$7.36
Fair Value$1.96
Quality53/100
Jiangsu Hengrui Medicine Co
600276.SHG · CNY · Health Care
-50%
upside to fair value
overvalued
Price¥52.11
Fair Value¥25.94
Quality59/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Xeris PharmaceuticalsJiangsu Hengrui Medicine Co
Valuation
105.7×P/E (TTM)43.6×
4.06×P/S (TTM)10.84×
—P/B5.76×
28.8×EV/EBITDA33.0×
—PEG0.93×
—Dividend yield0.4%
—Dividend per share¥0.20
Profitability
4%Net margin25%
10%Operating margin32%
—Return on equity15%
6%Return on assets9%
Growth
38%Revenue growth (YoY)13%
38.3%Avg. growth/yr (3Y)13.9%
154.7%Avg. growth/yr (5Y)2.5%
Balance & size
16.10×Debt / equity—
$1BMarket cap$52B
healthyGrowth qualityhealthy

Xeris Pharmaceuticals leads: 5 to 4 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Xeris Pharmaceuticalsof which business quality 50 · market factors 59 Jiangsu Hengrui Medicine Coof which business quality 68 · market factors 42
ProfitabilityMargins and returns on capital today
43
63
Quality GrowthAre margins and returns improving?
90
41
CashflowEarnings quality: real cash, not paper profit
73
82
Fin. StrengthBalance sheet, leverage, solvency risk
20
100
InvestmentDisciplined investing over empire-building
94
27
Low VolatilityCalm price path (market factor)
39
78
MomentumPrice trend over the last 3–12 months (market factor)
68
30
52W MomentumDistance to the 52-week high (market factor)
66
23
Net IssuanceBuybacks instead of dilution
0
64

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Xeris Pharmaceuticals

DCF Models$90.85
Earnings-Based$4.98
Dividend Discount$437
Multiples$24.92
Asset-Based$1.92
Growth DCF$105
Economic Profit$24.34
Growth Earnings$5.37

9 of 26 models see the stock below the current price.

Jiangsu Hengrui Medicine Co

DCF Models¥37.11
Earnings-Based¥21.29
Dividend Discount¥3.82
Multiples¥22.37
Asset-Based¥6.44
Growth DCF¥38.47
Economic Profit¥18.21
Growth Earnings¥29.68

26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Xeris Pharmaceuticals
Bear $1.01Fair Value $1.96Bull $2.43
$7.36 = current price (white tick)
Jiangsu Hengrui Medicine Co
Bear ¥19.95Fair Value ¥25.94Bull ¥40.28
¥52.11 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Xeris Pharmaceuticals · Health Care

Quality score53 · above median
Fair value upside-73% · bottom 25%

Jiangsu Hengrui Medicine Co · Health Care

Quality score59 · Top 25%
Fair value upside-50% · below median

Bottom line

As of Aug 8, 2026, Fair Value Calculator sees Jiangsu Hengrui Medicine Co as the less overvalued of the two: Xeris Pharmaceuticals trades at $7.36 versus a fair value of $1.96 (-73%), while Jiangsu Hengrui Medicine Co trades at ¥52.11 versus ¥25.94 (-50%).

Jiangsu Hengrui Medicine Co has the higher quality score (59/100).

See the full analysis →
Xeris Pharmaceuticals · Jiangsu Hengrui Medicine Co

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Xeris Pharmaceuticals

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Jiangsu Hengrui Medicine Co

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.